Company Sonnet BioTherapeutics Holdings, Inc.

SONN

US83548R3030

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-01 pm EDT			5-day change	1st Jan Change
1.86 ^USD	+5.08%		+0.81%	+6.90%

Mar. 11	Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	MT
Mar. 11	Top Premarket Gainers	MT

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Number of employees: 12

Managers	Title	Age	Since
John Cini FOU	Founder	72	10-12-31
Pankaj Mohan CEO	Chief Executive Officer	60	20-03-31
Jay Cross DFI	Director of Finance/CFO	53	19-04-30
Manuel Dafonseca CTO	Chief Tech/Sci/R&D Officer	-	21-03-21
Richard Kenney CTO	Chief Tech/Sci/R&D Officer	66	21-03-31
Susan Dexter CTO	Chief Tech/Sci/R&D Officer	67	20-03-31

Members of the board	Title	Age	Since
Raghu Rao BRD	Director/Board Member	62	20-03-31
Pankaj Mohan CEO	Chief Executive Officer	60	20-03-31
Donald Griffith BRD	Director/Board Member	75	20-03-31
Albert Dyrness BRD	Director/Board Member	61	20-03-31
Nailesh Bhatt BRD	Director/Board Member	52	20-03-31
Lori McNeill BRD	Director/Board Member	51	22-09-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,069,516	2,786,509 ( 90.78 %)	0	90.78 %

Name	Equities	%	Valuation
John Markey 6.460 %	198,300	6.460 %	368 838 $
Pankaj Mohan 2.038 %	62,572	2.038 %	116 384 $
Renaissance Technologies LLC 1.425 %	43,749	1.425 %	81 373 $
Citadel Securities GP LLC 0.9593 %	29,447	0.9593 %	54 771 $
Raghu Rao 0.5114 %	15,696	0.5114 %	29 195 $
Vanguard Group, Inc. (Subfiler) 0.4797 %	14,726	0.4797 %	27 390 $
Tower Research Capital LLC 0.0682 %	2,094	0.0682 %	3 895 $
John Cini 0.0596 %	1,830	0.0596 %	3 404 $
Susan Dexter 0.0498 %	1,530	0.0498 %	2 846 $
Nailesh Bhatt 0.0399 %	1,225	0.0399 %	2 279 $

Sonnet BioTherapeutics Holdings, Inc.

100 Overlook Center Suite 102

08540, Princeton

http://www.sonnetbio.com

address Sonnet BioTherapeutics Holdings, Inc.(SONN)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.86 USD

Average target price

12.5 USD

Spread / Average Target

+572.04%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
SONNET BIOTHERAPEUTICS HOLDINGS, INC.	+6.90%	5.43M
ELI LILLY AND COMPANY	+33.25%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.55%	348B
MERCK & CO., INC.	+18.16%	327B
ABBVIE INC.	+4.36%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.69%	147B

Other Pharmaceuticals